Advarra, the market leader in regulatory reviews and a leading provider of clinical research technology, today announced the ...

AT278 combines two fundamental properties, ultra-high concentration and an ultra-rapid profile, which provide the potential ...

SPEAR proposal reflects current evidence on monoclonal antibodies in treatment for Long COVID and identifies VYD2311 as a promising ...

PhaseV, a leader in AI/ML for clinical development, today announced a strategic partnership with Bioforum, a leading Contract ...

The CORE-MD (Coordinating Research and Evidence for high-risk Medical Devices) consortium has published new consensus ...

Clinical trial participants now expect clinical tools to match the usability of the digital tools they use every day.

The Foundation for Sarcoidosis Research (FSR) expresses both solidarity and resolve as aTyr Pharma announced that its Phase 3 trial of efzofitimod in pulmonary sarcoidosis did not meet its primary ...

"We are excited to see Pfizer advancing MesoC2 into clinical development rapidly, highlighting the potential of Nona's Harbour Mice® and integrated ADC platforms to deliver innovative cancer therapies ...

HAS COMMENCED RECRUITMENT IN THIS 36 PARTICIPANT STUDY PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / / Medicus Pharma Ltd. ...